在患者中,药物坚持和补充药物的使用之间的关系
Fatma Gündüz Oruç1, Gülden Atan2, Demet Şeker3
1Giresun University, Faculty of Health Sciences, Department of Internal Medicine Nursing, Giresun, Turkey.
Epilepsy & behavior : E&B
|March 28, 2024
概括
患者的药物坚持度是中度的,焦点患者的药物坚持度更好. 补充和综合医学 (CIM) 的使用,特别是祈祷,在患者中很常见.
科学领域:
- 神经学 神经学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 影响全球数以百万计的人,需要全面的管理策略.
- 补充和综合医学 (CIM) 越来越多地被用于治疗慢性疾病.
- 了解CIM的使用及其对症药物坚持的影响对于患者护理至关重要.
研究的目的:
- 研究患者 (PWE) 中CIM使用的流行率和模式.
- 评估PWE中CIM使用和药物坚持之间的关系.
- 确定PWE最常使用的CIM类型.
主要方法:
- 一项描述性,横截面研究,涉及土耳其大学医院的101名PWE.
- 数据采用描述形式和莫里斯基药物坚持度表-4 (MMS-4) 收集.
- 统计分析包括描述性统计,t测试,ANOVA和后期LSD测试.
主要成果:
- 平均MMS-4得分表明药物坚持程度中等 (3.08 ± 0.96).
- 类型显著影响了药物坚持得分 (F=3.998,p=0.021).
- 宗教人士的祈祷是最常见的CIM技术 (76.2%),被参与者用来改善一般健康或控制发作.
结论:
- 在研究的PWE群体中,药物坚持程度处于中等水平.
- 与一般性患者相比,患有焦点性和二次性全般性的个体表现出更好的药物坚持.
- 祈祷是PWE实践的CIM的主要形式,用于改善健康或控制发作.
相关概念视频
Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
288
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
288
Antiepileptic Drugs: Potassium Channel Activators
180
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
180
Antiepileptic Drugs: Glutamate Antagonists
338
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
338
Arteries of the Lower Limbs
188
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188
Antiepileptic Drugs: GABAergic Pathway Potentiators
389
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
389


